For the past two years, compounding pharmacies filled a critical gap: they made semaglutide and tirzepatide available at $150–$400/month while branded versions cost $900–$1,350. Millions of Americans accessed GLP-1 therapy through this pathway. Now, that door is closing.
Here's what's happening, why, and — most importantly — what your options are.
What's Happening with Compounded GLP-1s?
The story starts with the FDA shortage list. Under federal law, compounding pharmacies can produce copies of FDA-approved drugs only when those drugs are on the official FDA Drug Shortage List. Both semaglutide and tirzepatide were listed as in shortage beginning in 2022–2023, which gave compounders legal standing to produce them.
As of late 2025 and into 2026, the FDA has been taking steps to remove or restrict these shortage designations as manufacturers increased supply:
- Semaglutide (Ozempic/Wegovy): Removed from the FDA shortage list. 503B outsourcing facilities (bulk compounders) can no longer legally produce it under the shortage exemption. However, 503A patient-specific compounding pharmacies can still legally compound semaglutide in many states under traditional compounding rules — this is an important distinction. The situation is complex and varies by state.
- Tirzepatide (Mounjaro/Zepbound): As of early April 2026, tirzepatide remains on the FDA shortage list, meaning compounding is still broadly legal for both 503A and 503B pharmacies. However, Eli Lilly has aggressively pursued legal action against some compounders.
The Legal Landscape
Several compounding pharmacy trade groups have filed legal challenges against the FDA's shortage determinations, arguing that the supply isn't truly sufficient to meet demand. Some of these cases are still in courts. However, the trend is clearly toward tighter enforcement:
- The FDA has issued warning letters to compounders producing semaglutide and tirzepatide
- Several compounding pharmacies have voluntarily stopped producing these medications
- State boards of pharmacy are increasing oversight
- Some telehealth platforms that primarily dispensed compounded GLP-1s have pivoted to other medications
What This Means for You
If you're currently using compounded semaglutide or tirzepatide:
- Don't panic. Transitions are happening over months, not days. You have time to work with your healthcare provider on an alternative.
- Don't stockpile. Compounded medications have limited shelf life and potency can degrade.
- Talk to your provider. Start the conversation about branded alternatives and savings programs now, before your current supply runs out.
Your Options in 2026
Option 1: Foundayo (Orforglipron) — The New Affordable Branded GLP-1
Foundayo launched in 2026 with pricing specifically designed to capture patients leaving compounded GLP-1s:
- Self-pay: $149–$249/month (comparable to compounded semaglutide pricing)
- With savings card: $25/month for commercially insured patients
- Medicare: $50/month starting July 2026
- Advantages: FDA-approved, guaranteed quality and potency, oral tablet (no injections), room-temperature storage
For most patients transitioning from compounded semaglutide, Foundayo is the most direct replacement in terms of cost and convenience. See our Foundayo pricing guide for details.
Option 2: Brand-Name Medications with Savings Programs
Every major GLP-1 manufacturer offers savings programs:
| Medication | Savings Program | Price with Savings | Eligibility |
|---|---|---|---|
| Foundayo | Savings Card | $25/mo | Commercial insurance |
| Wegovy | Savings Card | $25/mo | Commercial insurance |
| Zepbound | LillyDirect / Savings Card | $499/mo (self-pay) or $25/mo (insured) | All patients / Commercial insurance |
| Ozempic | Savings Card | $25/mo | Commercial insurance (diabetes) |
| Mounjaro | Savings Card | $25/mo | Commercial insurance (diabetes) |
Key insight: If you have commercial health insurance, you can likely get a branded GLP-1 for $25/month — potentially cheaper than what you were paying for compounded versions.
Option 3: Medicare Part D Coverage
New in 2026: The Medicare GLP-1 Bridge program (July 1 – December 31, 2026) covers Wegovy and Zepbound for obesity at a $50/month copay. Separately, Eli Lilly has committed to $50/month Medicare pricing for Foundayo starting July 2026. Note: Ozempic, Rybelsus, and Mounjaro are covered under Medicare for diabetes only, not for weight loss. Starting January 2027, the permanent BALANCE Model will provide ongoing coverage (not all plans required to participate). See our Medicare GLP-1 coverage guide.
Option 4: Patient Assistance Programs
For patients who are uninsured and meet income requirements:
- Lilly Cares: May provide Foundayo and Zepbound at no cost
- Novo Nordisk PAP: May provide Wegovy and Ozempic at no cost
- Eligibility typically requires household income below 400% of the federal poverty level
- Apply through your prescriber's office or directly through manufacturer websites
A Note on Quality and Safety
This section isn't about fearmongering — many compounding pharmacies produce quality products. But it's important to understand the differences:
- FDA-approved medications undergo rigorous testing for potency, purity, sterility, and consistency. Every batch is manufactured to the same standard.
- Compounded medications are not FDA-approved and are not subject to the same manufacturing standards. Quality varies between pharmacies. The FDA has found potency issues (too much or too little active ingredient) in sampled compounded GLP-1 products.
- Salt form matters: Many compounders use semaglutide sodium salt rather than the base form used in Ozempic/Wegovy, which may have different bioavailability characteristics.
This doesn't mean compounded semaglutide is dangerous — many patients have used it successfully. But FDA-approved medications offer a level of quality assurance that compounded products cannot match.
Building Your Transition Plan
If you need to transition away from compounded GLP-1s, here's a practical approach:
- Schedule a conversation with your healthcare provider specifically about GLP-1 transition planning
- Check your insurance formulary — call the number on your insurance card and ask which GLP-1 medications are covered and at what tier
- Explore savings programs for every covered medication (links in the table above)
- Consider Foundayo as a self-pay option if insurance coverage is limited
- Don't go cold turkey — work with your provider to overlap or properly transition between medications to avoid GLP-1 withdrawal effects (appetite rebound, blood sugar changes)
- Use the MedSwitcher calculator to plan your specific transition timeline and compare costs
The Bottom Line
The compounded GLP-1 era isn't ending overnight, but the trajectory is clear. The good news is that 2026 offers more affordable branded options than ever before — particularly Foundayo, which was priced to fill exactly this gap. With savings cards, Medicare coverage, and patient assistance programs, most patients can find an FDA-approved GLP-1 at a price they can sustain.
Start planning your transition now. Don't wait until your compounding pharmacy stops filling orders.
Sources
- FDA. Drug Shortage Database: Semaglutide. FDA.gov. Accessed April 2026.
- FDA. Warning Letters to Compounding Pharmacies. FDA.gov. 2025–2026.
- Outsourcing Facilities Association. Legal filings regarding FDA shortage determinations. 2025.
- Eli Lilly. Foundayo (orforglipron) Pricing and Access Programs. 2026.
- CMS. Medicare Part D Weight Management Coverage Update. 2026.